Targeting macrophage activation with the DPP4 inhibitor anagliptin has also been performed in genetically obese melanocortin 4 receptor-deficient (MC4R-KO) mice, which develop hepatic steatosis, NASH, and HCC in the presence of obesity and insulin resistance [80]. This evidence concerns the gene DPP4 and Insulin resistance.